What is the highest dose of Mounjaro, and how do patients reach it?

Step 1: why the schedule starts at 2.5mg, not 15mg

Mounjaro's titration schedule is not about building up to the "real" medicine. The lower doses are therapeutic in their own right; the slower climb exists to allow your digestive system to adjust. Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) and that dual action slows gastric emptying noticeably. Starting at a lower strength reduces the early nausea, vomiting and indigestion that would otherwise push people to stop treatment altogether.

The first KwikPen delivers 2.5mg weekly for roughly four weeks, and our 2.5mg Mounjaro guide explains what to expect during that opening phase in detail. That window is clinically important: your body is adapting, and your prescriber is watching. There is no benefit, and real risk, in jumping steps. The NHS patient information for tirzepatide is clear that the starting dose is a tolerability measure; dose changes follow prescriber review, not a fixed calendar.

A small routine helps here. Many people keep the pen in the fridge door so it becomes as automatic as reaching for the milk on the same morning each week. Consistency with timing is part of what makes the schedule work.

Step 2: climbing through the intermediate doses toward the highest Mounjaro dose

After 2.5mg, the typical sequence runs 5mg, 7.5mg, 10mg and 12.5mg, each held for approximately four weeks before the next increase. "Approximately" is doing real work in that sentence: your prescriber may hold a dose longer if side effects are still settling, or if your progress plateaus and needs assessment.

For a closer look at how one of the earlier steps fits into the broader schedule, the 5mg Mounjaro guide covers what that phase typically involves. And if you are deciding between dose options or wondering what the full titration picture looks like, the Mounjaro overview page pulls together the licensed uses, trial evidence and eligibility criteria in one place.

NICE's appraisal of tirzepatide (TA1026, published December 2024) reviewed the clinical evidence across the full dose range and recommended the medicine for adults meeting specific BMI and comorbidity thresholds. The SURMOUNT-1 trial, which underpins much of that evidence, randomised 2,539 adults and reported average body-weight reductions of around 20 to 21 percent at the highest dose over 72 weeks. Those figures came from people who reached and maintained 15mg; results at lower maintenance doses are meaningful but typically more modest.

Step 3: what reaching the highest dose of Mounjaro actually means

Arriving at 15mg is not the endpoint of treatment, it is where the maintenance phase begins for people who have titrated fully, and our highest dosage of Mounjaro page explains what that maintenance phase involves and how to approach it safely. At this strength, Mounjaro carries a Black Triangle (▼) designation from the MHRA, meaning it remains under additional monitoring as post-market safety data continues to accumulate. That is standard for newer medicines and does not indicate exceptional risk; it simply means the regulator wants ongoing reporting.

Reaching 15mg requires clinical review at each prior step. At nume, a GPhC-registered Independent Prescriber reads your case before every dose increase, not an automated system, a real clinician. If a patient is transferring from another provider at a higher dose, evidence of that existing treatment is reviewed before the next supply is confirmed.

If you are weighing up what treatment might cost across the titration journey, the Mounjaro pricing page sets out the honest cost picture for private treatment in the UK, including what a legitimate price should cover. One transparent figure that includes consultation, prescription and next-day delivery is a reasonable baseline expectation.

When 15mg may not be the right destination

Not every patient will need the highest Mounjaro dose, and clinical guidelines do not require it. NICE TA1026 notes that continuing treatment should be reviewed if less than five percent weight loss has occurred after six months at the highest tolerated dose, but "highest tolerated" is the operative phrase. A prescriber may find that a patient does well at 10mg or 12.5mg, tolerates it comfortably, and has no clinical reason to push further.

Common side effects across all doses are gastrointestinal: nausea, loose stools, constipation, burping and reflux are the ones most frequently reported in trials, and they tend to be at their most pronounced after starting a new strength before settling over the following week or two. The highest-dose tirzepatide page covers the side-effect profile at 15mg in more detail, including what to monitor and when to contact a prescriber.

If you are not on Mounjaro yet and want to understand the full process (eligibility, clinical assessment, what happens after approval) our weight-loss treatments page is the right starting point. Check your eligibility and speak to our prescribers about whether Mounjaro is clinically suitable for you.